Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Singapore-based biotechnology company S Bio has initiated a Phase I/II clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in medical centers in Australia for patients with chronic idiopathic myelofibrosis.
Subscribe to our email newsletter
The trial is designed to evaluate the safety and tolerability of SB1518 in patients with chronic idiopathic myelofibrosis (CIMF) and is expected to enroll up to 50 patients.
The Phase I part of the study will assess the safety profile and evaluate the pharmacokinetic and pharmacodynamic activities of SB1518, and the Phase II component will assess the clinical benefits and continue to evaluate the safety profile of SB1518.
Jan-Anders Karlsson, CEO of S Bio, said: “We are pleased with the advancement of our JAK2 inhibitor into a Phase I/II clinical trial in Australia as it exemplifies the expansion of our company’s global development strategy.
“SB1518’s strengths are in its exciting anti-proliferative and anti-tumor activity, as demonstrated by a range of in vitro and in vivo models, as well as its excellent tolerability. We believe this compound may eventually provide oncologists with a much needed and improved option to treat patients suffering from CIMF.”